Dihexa
Animal / preclinicalAlso known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A small angiotensin IV–derived peptide from Alzheimer's research, reported in its originating lab to be orders of magnitude more potent than BDNF at driving new synapse formation in rodent models. Human studies haven't happened, and its growth-factor mechanism is the open safety question.
Mechanism
Enhances hepatocyte growth factor (HGF)/c-Met signalling, promoting synaptogenesis in animal models — potent biology that is also why long-term safety is unstudied territory.
Evidence
Striking rodent synaptogenesis and cognition data from the originating lab; no human studies, and the potent HGF/c-Met mechanism is unexplored in people.
Community-reported information
Community reports vary. Anecdotal, unvalidated and poorly characterised; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Not well characterised in humans (oral/transdermal use reported).
Storage
Store cool and dark.
Commonly reported side effects
- Not well characterised in humans
Legal status by region
- USNot FDA-approved; not a lawful supplement ingredient.
Legal status changes over time; verify locally before relying on this.